DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of ...

BNT327/PM8002 has shown encouraging efficacy and tolerability in patients across various tumor types, with more than 700 patients treated in clinical trials to date.

BNT327, BioNTech’ s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

With the acquisition, BNTX will gain full global rights to BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A, which is currently being developed in mid-to-late-stage ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

BioNTech’s BNT327 is currently under extensive evaluation in multiple ongoing clinical trials, with over 1,000 patients having received the treatment to date.

BioNTech SE and Bristol Myers Squibb announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to ...

BioNTech's BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date.

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...